NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] READ MORE
Updated January 4, 2021 New York, NY– December 16, 2020. More than half of people with lupus (54%) are willing to take a COVID-19 vaccine if it is free and determined safe by scientists according to results of a survey conducted by the Lupus Research Alliance (LRA). However, it is important to note that 24% […] READ MORE
December 14, 2020 In a recent study published in the Journal of Immunology, LRA-funded researcher Dr. John Zhang at Medical University of South Carolina found that a protein called Fli-1 causes immune cells to produce a molecule that causes inflammation. When Fli-1 was hindered by the chemotherapeutic drug camptothecin, immune cells produced fewer inflammatory molecules. […] READ MORE
1 in 2 Lupus Nephritis Patients Don’t Know They Have Lupus New York, NY– December 7, 2020. Significant gaps in education and communication among patients and physicians pose barriers to lupus nephritis (LN) care, according to results of two companion surveys conducted by the National Kidney Foundation (NKF) and the Lupus Research Alliance (LRA). Half […] READ MORE
NEW YORK, NY. December 3, 2020 – The Lupus Research Alliance is proud to announce the 2020 recipients of its Lupus Mechanisms and Targets Award (LMTA). The highly competitive grant gives researchers up to $200,000 a year for up to three years. As indicated by the title of the award, the 2020 awardees are each […] READ MORE
December 2, 2020 The immune response during severe COVID-19 is similar to a lupus complication known as antiphospholipid syndrome, according to a study partly funded by the Lupus Research Alliance. Dr. Jason Knight and his colleagues including rheumatologist Yu (Ray) Zuo and cardiologist Yogen Kanthi reported that 52% of patients hospitalized with severe COVID-19 had […] READ MORE
November 30, 2020 Every year, on December 1, the world shows its heartfelt support for the Lupus Research Alliance and other non-profit organizations. Giving Tuesday “is a global generosity movement unleashing the power of people and organizations to transform their communities and the world.” Donate here to give the most priceless gift – research to […] READ MORE
Global Lupus Community Rallied by Lady Gaga, Selena Gomez, Norm Lewis and a Host of Inspiring Lupus Advocates New York, NY. November 24, 2020 – The Lupus Research Alliance (LRA)’s 2020 Virtual Fundraising Event surpassed its goal last night, raising $3.1 million for lupus research programs. Led by inspiring words from Lady Gaga and Selena Gomez […] READ MORE
November 23, 2020 Up to 95% of lupus patients report pain and fatigue caused by the disease. To explore ways to fix this, a research team led by Dr. Cynthia Aranow at The Feinstein Institutes for Medical Research studied whether lessening inflammation in patients with lupus would also lessen pain and fatigue. In this study, […] READ MORE
November 19, 2020 Lady Gaga and Selena Gomez Invite Global Lupus Community New York, NY. November 19 – The Lupus Research Alliance (LRA) is taking the show on-line this year with a preeminent virtual Fundraising Event celebrating extraordinary scientific achievements. Performances will include a special tribute by the one-and-only Lady Gaga and a solo by Broadway […] READ MORE
November 19, 2020 The Lupus Research Alliance supported an impressive number — 30+ — of studies presented at ACR Convergence 2020, this year’s meeting of the American College of Rheumatology. Each year, researchers are selected to share their discoveries in talks and poster sessions, allowing medical professionals to keep up to date with the latest […] READ MORE
November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE). AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […] READ MORE
